One of the most defining developments in contemporary healthcare is the transition from activity-based to value-based delivery. Currently, many healthcare providers are remunerated based on their level of activity, which encourages focus on activities rather than improvements in patient health and life quality. The introduction of value-based payment schemes, which reward better patient outcomes, is an essential part in creating the healthcare providers of tomorrow, where patients’ quality of life is the main objective.
The introduction of value-based healthcare will have a variety of implications for healthcare providers, payers, patients and the life sciences industry. One implication will be a change towards much more individualized patient care than the predominantly standardized treatment packages of today, especially for the growing number of chronically ill patients in need of long-term care. Continued development towards value-based healthcare will reveal further implications, which may disrupt current business models, as well as creating new possibilities.
The life sciences industry is an increasingly important part of many national economies and plays a vital role in creating research-based economic growth. In order to uphold or grow strong clusters, governments and industry leaders are turning to national strategies for their life sciences clusters. These strategies shed light on solutions to challenges regarding attraction and retention of companies and skilled personnel. The conditions offered to perform R&D, and in particular clinical research, are central criteria when assessing the attractiveness of a jurisdiction.
Our Healthcare & Life Sciences team helps clients adapt to new regulatory landscapes such as the ongoing transition from activity-based to value-based healthcare delivery and to stay attractive in the global competition for life sciences industry.